Induction of an acute phase response after OKT3 therapy.
Pohanka
E
E
Second Department of Medicine, University of Vienna, Austria.
Kovarik
J
J
Klauser
R
R
Woloszcsuk
W
W
Zlabinger
G J
GJ
D000209:Acute-Phase Proteins / Q000378:metabolism; D016207:Cytokines / Q000097:blood; D006084:Graft Rejection; D006801:Humans; D007371:Interferon-gamma / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology*; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012016:Reference Values; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000209:Acute-Phase Proteins; D016207:Cytokines; D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma